Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells

British Journal of Pharmacology

Volumn 143, Issue 6, 2004, Pages 715-724

  Werner, Martin ^a   Sacher, Julia ^a   Hohenegger, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Bax; Doxorubicin; HMG CoA reductase inhibitors; RD cells; Rhabdomyosarcoma; Statins

Indexed keywords

BONGKREKIC ACID; CALPAIN; CASPASE 3; CASPASE 9; DOXORUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PROTEIN BAX; SIMVASTATIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RHABDOMYOMA;

APOPTOSIS; CASPASES; DOXORUBICIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MITOCHONDRIA; RHABDOMYOSARCOMA; TUMOR CELLS, CULTURED;

EID: 10044263388     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705928     Document Type: Article

References (44)

1. AGARWAL, B., RAO, C.V., BHENDWAL, S., RAMEY, W.R., SHIRIN, H., REDDY, B.S. & HOLT, P.R. (1999). Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology, 117, 838-847.
2. BELLOSTA, S., FERRI, N., BERNINI, F., PAOLETTI, R. & CORSINI, A. (2000). Non-lipid-related effects of statins. Ann. Med., 32, 164-176.
3. BJERRE, L.M. & LELORIER, J. (2001). Do statins cause cancer? A meta-analysis of large randomised clinical trials. Am. J. Med., 110, 716-723.
4. BLAIS, L., DESGAGNE, A. & LELORIER, J. (2000). 3-Hydroxy-3- methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch. Intern. Med., 160, 2363-2368.
5. CHAN, K.K., OZA, A.M. & SIU, L.L. (2003). The statins as anticancer agents. Clin. Cancer Res., 9, 10-19.
6. CLUTTERBUCK, R.D., MILLAR, B.C., POWLES, R.L., NEWMAR A., CATOVSKY, D., JARMAN, M. & MILLAR, J.L. (1998). Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice. Br. J. Haematol., 102, 522-527.
7. CORSINI, A., BELLOSTA, S., BAETTA, R., FUMAGALLI, R., PAOLETTI, R. & BERNINI, F. (1999). New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther., 84, 413-428.
8. CORSINI, A., MAGGI, F.M. & CATAPANO, A.L. (1995). Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol. Res., 31, 9-27.
9. DEBATIN, K.M., PONCET, D. & KROEMER, G. (2002). Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene, 21, 8786-8803.
10. DIMITROULAKOS, J., YE, L.Y., BENZAQUEN, M., MOORE, M.J., KAMEL-REID, S., FREEDMAN, M.H., YEGER, H. & PENN, L.Z. (2001). Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin. Cancer Res., 7, 158-167.
11. FERRI, K.F. & KROEMER, G. (2001). Organelle-specific initiation of cell death pathways. Nat. Cell Blol. 3, E255-E263.
12. FRITZ, G., BRACHETTI, C. & KAINA, B. (2003). Lovastatin causes sensitization of HeLa cells to ionizing radiation-induced apoptosis by the abrogation of G2 blockage. Int. J. Radiat. Biol., 79, 601-610.
13. GOLDSTEIN, J.L. & BROWN, M.S. (1990). Regulation of the mevalonate pathway. Nature, 343, 425-430.
14. HAJNOCZKY, G., DAVIES, E. & MADESH, M. (2003). Calcium signaling and apoptosis. Biochem. Biophys. Res. Commun., 304, 445-454.
15. HAWK, M.A., CESEN, K.T., SIGLIN, J.C. STONER, G.D. & RUCH, R.J. (1996). Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. Cancer Lett., 109, 217-222.
16. HORTOBAGYI, G.N. (1997). Anthracyclines in the treatment of cancer. An overview. Drugs, 54, 1-7.
17. IGNEY, F.H. & KRAMMER, P.H. (2002). Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer, 2, 277-288.
18. JAKOBISIAK, M., BRUNO, S., SKIERSKI, J.S. & DARZYNKIEWICZ, Z. (1991). Cell cycle-specific effects of lovastatin. Proc. Natl. Acad. Sci. U.S.A., 88, 3628-3632.
19. KAWATA, S., YAMASAKI, E., NAGASE, T., INUI, Y., ITO, N., MATSUDA, Y., INADA, M., TAMURA, S., NODA, S., IMAI, Y. & MATSUZAWA, Y. (2001). Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer. 84, 886-891.
20. KEYOMARSI, K., SANDOVAL, L., BAND, V. & PARDEE, A.B. (1991). Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res., 51, 3602-3609.
21. KIKUCHI, T., NAGATA, Y. & ABE, T. (1997). In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells. J. Neurooncol., 4, 233-239.
22. KIM, W.S., KIM, M.M., CHOI, H.J., YOON, S.S., LEE, M.H., PARK, K., PARK, C.H. & KANG, W.K. (2001). Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest. New Drugs. 19, 81-83.
23. KLINGENBERG, M. (1980). The ADP-ATP translocation in mitochondria, a membrane potential controlled transport. J. Membr. Biol., 56, 97-105.
24. KOSCIELNIAK, E., MORGAN, M. & TREUNER, J. (2002). Soft tissue sarcoma in children: prognosis and management. Paediatr. Drugs, 4, 21-28.
25. KRITCHEVSKY, S.B. & KRITCHEVSKY, D. (1992). Serum cholesterol and cancer risk: an epidemiologic perspective. Annu. Rev. Niur., 12, 391-416.
26. LARNER, J., JANE, J., LAWS, E., PACKER, R., MYERS, C. & SHAFFREY, M. (1998). A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am. J. Clin. Oncol., 21, 579-583.
27. LI, H.Y., APPELBAUM, F.R., WILLMAN, C.L., ZAGER, R.A. & BANKER, D.E. (2003). Cholesterol-modulating agents kill acute inyeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood, 101, 3628-3634.
28. LUO, X., BUDIHARDJO, I., ZOU, H., SLAUGHTER, C. & WANG, X. (1998). Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 94, 481-490.
29. MANDIC, A., VIKTORSSON, K., STRANDBERG, L., HEIDEN, T., HANSSON, J., LINDER, S. & SHOSHAN, M.C. (2002). Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis. Mol. Cell. Biol., 22, 3003-3013.
30. MCDOWELL, H.P. (2003). Update on childhood rhabdomyosarcoma. Arch. Dis. Child., 88, 354-357.
31. MCPAKE, C.R., TILLMAN, D.M., POQUETTE, C.A., GEORGE, E.O., HOUGHTON, J.A. & HARRIS, L.C. (1998). Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status. Oncol. Res., 10, 235-244.
32. MUNDY, G., GARRETT, R., HARRIS, S., CHAN, J., CHEN, D., ROSSINI, G., BOYCE, B., ZHAO, M. & GUTIERREZ, G. (1999). Stimulation of bone formation in vitro and in rodents by statins. Science, 286, 1946-1949.
33. MUNRO, E., PATEL, M., CHAN, P., BETTERIDGE, L., CLUNN, G., GALLAGHER, K., HUGHES, A., SCHACHTER, M., WOLFE, J. & SEVER, P. (1994). Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur. J. Clin. Invest., 24, 766-772.
34. NEWMAN, T.B. & HULLEY, S.B. (1996). Carcinogenicity of lipid-lowering drugs. JAMA, 275, 55-60.
35. RAO, S., LOWE, M., HERLICZEK, T.W. & KEYOMARSI, K. (1998). Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogens, 17, 2393-2402.
36. S4 GROUP; SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet, 344, 1383-1389.
37. S4 GROUP; SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP (2000). Follow-up study of patients randomised in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am. J. Cardiol., 86, 257-262.
38. THIBAULT, A., SAMID, D., TOMPKINS, A.C., FIGG, W.D., COOPER, M.R., HOHL, R.J., TREPEL, J., LIANG, B., PATRONAS, N., VENZON, D.J., REED, E. & MYERS, C.E. (1996). Phase 1 study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res., 2, 483-491.
39. TOMEK, S., KOESTLER, W., HORAK, P., GRUNT, T., BRODOWICZ, T., PRIBILL, I., HALASCHEK, J., HALLER, G., WILTSCHKE, C. ZIELINSKI, C.C. & KRAINER, M. (2003). Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur. J. Cancer, 39, 1318-1329.
40. VAUGHAN, C.J. (2003). Prevention of stroke and dementia with statins: effects beyond lipid lowering. Am. J. Cardiol., 91, 23B-29B.
41. WANG, K.W.K. (2000). Calpain and caspase: can you tell the difference? Trends Neursci., 23, 20-26.
42. WEI, M.C., ZONG, W.X., CHENG, E.H., LINDSTEN, T., PANOUTSA-KOPOULOU, V., ROSS, A.J., ROTH, K.A., MACGREGOR, G.R., THOMPSON, C.B. & KORSMEYER, S.J. (2001). Proapoptotic BAX and BAK.: a requisite gateway to mitochondrial dysfunction and death. Science, 292, 727-730.
43. WEITZ-SCHMIDT, G. (2002). Statins as anti-inflammatory agents. Trends Pharmacol. Sci., 23, 482-486.
44. WONG, W.W., DIMITROULAKOS, J., MINDEN, M.D. & PENN, L.Z. (2002). HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 16, 508-519.